The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer

被引：0
|
作者：
Sanchez-Martin, Francisco J.
Dalmases, Alba
Bellosillo, Beatriz
Argiles, Guillem
Gelabert, Mariona
Canadas, Israel
Vidal, Joana
Siravegna, Giulia
Arena, Sabrina
Koefoed, Klaus
Visa, Laura
Arpf, Oriol
Horak, Ivan D.
Iglesias, Mar
Stroh, Christopher
Kragh, Michael
Rovira, Ana
Albanell, Joan
Bardelli, Alberto
Tabernero, Josep
Montagut, Clara
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2149
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Dienstmann, Rodrigo
    Tabernero, Josep
    Van Cutsem, Eric
    Cervantes-Ruiperez, Andres
    Keranen, Susana Rosello
    Vinuales, Marta Benavent
    Kjaer, Ida
    Pedersen, Mikkel W.
    Skartved, Niels Jorgen Ostergaard
    Flensburg, Mimi F.
    Horak, Ivan David
    Garcia-Carbonero, Rocio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S)
    Tabernero, J.
    Ciardiello, F.
    Montagut, C.
    Ding, C.
    Kopetz, S.
    Poulsen, T. Tuxen
    Bardelli, A.
    Wyrwicz, L.
    Cubillo, A.
    Santos, C.
    Fumi, G.
    Zagonel, V.
    Bennouna, J.
    Siena, S.
    Falcone, A.
    Benavent, M.
    Argiles, G.
    Kragh, M.
    Horak, I. D.
    Dvorkin, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Preclinical efficacy of Sym004, novel anti-EGFR antibody, in esophageal squamous cell carcinoma cell lines
    Fukuoka, Shota
    Kojima, Takashi
    Koga, Yoshikatsu
    Yamauchi, Mayumi
    Komatsuzaki, Rie
    Aoyagi, Kazuhiko
    Sasaki, Hiroki
    Yasunaga, Masahiro
    Matsumura, Yasuhiro
    Kuronita, Toshio
    Doi, Toshihiko
    Ohtsu, Atsushi
    CANCER RESEARCH, 2015, 75
  • [24] Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
    Montagut, Clara
    Argiles, Guillem
    Ciardiello, Fortunato
    Poulsen, Thomas T.
    Dienstmann, Rodrigo
    Kragh, Michael
    Kopetz, Scott
    Lindsted, Trine
    Ding, Cliff
    Vidal, Joana
    Clausell-Tormos, Jenifer
    Siravegna, Giulia
    Sanchez-Martin, Francisco J.
    Koefoed, Klaus
    Pedersen, Mikkel W.
    Grandal, Michael M.
    Dvorkin, Mikhail
    Wyrwicz, Lucjan
    Rovira, Ana
    Cubillo, Antonio
    Salazar, Ramon
    Desseigne, Francoise
    Nadal, Cristina
    Albanell, Joan
    Zagonel, Vittorina
    Siena, Salvatore
    Fumi, Guglielmo
    Rospo, Giuseppe
    Nadler, Paul
    Horak, Ivan D.
    Bardelli, Alberto
    Tabernero, Josep
    JAMA ONCOLOGY, 2018, 4 (04)
  • [25] Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
    Napolitano, Stefania
    Martini, Giulia
    Rinaldi, Barbara
    Martinelli, Erika
    Donniacuo, Maria
    Berrino, Liberato
    Vitagliano, Donata
    Morgillo, Floriana
    Barra, Giusy
    De Palma, Raffaele
    Merolla, Francesco
    Ciardiello, Fortunato
    Troiani, Teresa
    CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2975 - 2983
  • [26] GC1118, a new anti-EGFR antibody overcome acquired resistance to cetuximab in colorectal cancer xenograft model
    Lee, Shi-Nai
    Cho, Hyun-Jung
    Lim, Yangmi
    Hur, Minkyu
    Lee, Eun Hee
    Lee, Jae-Chul
    Lee, Kyuhyun
    Kim, Sujeong
    Won, Jonghwa
    CANCER RESEARCH, 2016, 76
  • [27] AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
    Ye, Hua
    Liu, Yi
    Wu, Kefeng
    Luo, Hui
    Cui, Liao
    CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
  • [28] AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
    Hua Ye
    Yi Liu
    Kefeng Wu
    Hui Luo
    Liao Cui
    Cell Communication and Signaling, 18
  • [29] Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients' avatars
    Bardelli, Alberto
    Misale, Sandra
    Arena, Sabrina
    Siravegna, Giulia
    Lamba, Simona
    Bencardino, Katia
    Amatu, Alessio
    Valtorta, Emanuele
    Lauricella, Calogero
    Sarlore-Bianchi, Andrea
    Di Nicolantonio, Federica
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Nonclinical safety and pharmacokinetics of Sym004: A synergistic anti-EGF receptor antibody mixture
    Skartved, Niels Jorgen
    Pedersen, Mikkel W.
    Jacobsen, Helle
    Jorgensen, Thomas K.
    Kragh, Michael
    CANCER RESEARCH, 2011, 71
12345